{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:51:44Z","timestamp":1786121504625,"version":"build-2736575974"},"reference-count":25,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tapinarof cream 1%, a non\u2010steroidal topical aryl hydrocarbon receptor\u2010modulating agent, is approved in Japan for atopic dermatitis (AD) and plaque psoriasis. Real\u2010world data on longitudinal outcomes, treatment continuation, interruption and restart, and adverse\u2010event timing are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single\u2010center retrospective study included patients newly prescribed tapinarof cream 1% from November 2024 to July 24, 2025. The full analysis set comprised 37\u2009AD and 58 plaque psoriasis patients. Primary endpoints were Eczema Area and Severity Index 50% improvement (EASI50) at week 8 for AD and Psoriasis Area and Severity Index 75% improvement (PASI75) at week 12 for psoriasis. Observed\u2010case and non\u2010responder imputation (NRI) analyses were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In AD, week\u20108 EASI50 was achieved by 12\/24 evaluable patients (50.0%) and 12\/37 under NRI (32.4%). Mean EASI decreased from 5.94 at baseline to 2.56 at week 8 and 0.83 at week 52. Week\u201052 EASI was available for 13\/37 overall (13\/27 with ascertainable status at the data cutoff). In psoriasis, week\u201012 PASI75 was achieved by 15\/33 evaluable patients (45.5%) and 15\/58 under NRI (25.9%). Mean PASI decreased from 2.95 at baseline to 1.18 at week 12 and 0.43 at week 52. Week\u201052 PASI was available for 25\/58 overall (25\/49 with ascertainable status at the data cutoff); long\u2010term summaries were observed\u2010case and potentially responder\u2010enriched. Any adverse event was recorded in 11\/37\u2009AD patients and 12\/58 psoriasis patients. Median headache onset was 8\u2009h in AD and 1.8\u2009days in psoriasis. No serious drug\u2010related adverse event was recorded. No pigmentary change was documented; however, without standardized colorimetry or photography, its absence cannot be confirmed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tapinarof\u2010containing treatment was associated with clinically meaningful improvement in AD and plaque psoriasis in routine practice, although frequent concomitant therapy, observed\u2010case long\u2010term analyses, and retrospective ascertainment limit causal and safety inferences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1346-8138.70448","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:19:11Z","timestamp":1786079951000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Effectiveness, Treatment Course, and Safety of Tapinarof Cream 1% for Atopic Dermatitis and Plaque Psoriasis in Japan"],"prefix":"10.1111","author":[{"given":"Kanade","family":"Iino","sequence":"first","affiliation":[{"name":"Department of Dermatology Saitama Medical Center, Saitama Medical University  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6614-8492","authenticated-orcid":false,"given":"Saori","family":"Takamura","sequence":"additional","affiliation":[{"name":"Department of Dermatology Saitama Medical Center, Saitama Medical University  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Dermatology Saitama Medical Center, Saitama Medical University  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"VTAMA (tapinarof) cream for topical use. Full prescribing information 2025Organon LLC."},{"key":"e_1_2_10_3_1","unstructured":"Vtama Cream 1% interview form 2025Torii Pharmaceutical Co. Ltd."},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the Treatment of Psoriasis: A Review of the Unique Mechanism of Action of a Novel Therapeutic Aryl Hydrocarbon Receptor\u2010Modulating Agent","volume":"84","author":"Bissonnette R.","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof Is a Natural AhR Agonist That Resolves Skin Inflammation in Mice and Humans","volume":"137","author":"Smith S. H.","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215424","article-title":"Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis","volume":"20","author":"Furue M.","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2014.04.019","article-title":"Activation of the Aryl Hydrocarbon Receptor Dampens the Severity of Inflammatory Skin Conditions","volume":"40","author":"Di Meglio P.","year":"2014","journal-title":"Immunity"},{"key":"e_1_2_10_8_1","first-page":"917","article-title":"Coal Tar Induces AHR\u2010Dependent Skin Barrier Repair in Atopic Dermatitis","volume":"123","author":"Bogaard E. H.","year":"2013","journal-title":"Journal of Clinical Investigation"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/1346-8138.17451","article-title":"Tapinarof Cream for the Treatment of Atopic Dermatitis: Efficacy and Safety Results From Two Japanese Phase 3 Trials","volume":"51","author":"Igarashi A.","year":"2024","journal-title":"Journal of Dermatology"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/1346-8138.17423","article-title":"Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety Results From Two Japanese Phase 3 Trials","volume":"51","author":"Igarashi A.","year":"2024","journal-title":"Journal of Dermatology"},{"key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis","volume":"385","author":"Lebwohl M. G.","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_10_12_1","first-page":"457","article-title":"Tapinarof Cream 1% Once Daily in Atopic Dermatitis: Results From ADORING 1 and ADORING 2","volume":"91","author":"Silverberg J. I.","year":"2024","journal-title":"Journal of the American Academy of Dermatology"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaad.2022.06.1171","article-title":"One\u2010Year Safety and Efficacy of Tapinarof Cream for the Treatment of Plaque Psoriasis: Results From the PSOARING 3 Trial","volume":"87","author":"Strober B.","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic Dermatitis","volume":"396","author":"Langan S. M.","year":"2020","journal-title":"Lancet"},{"key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of Care for the Management of Atopic Dermatitis: Section\u00a02. Management and Treatment of Atopic Dermatitis With Topical Therapies","volume":"71","author":"Eichenfield L. F.","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong A. W.","year":"2020","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths C. E. M.","year":"2021","journal-title":"Lancet"},{"key":"e_1_2_10_18_1","first-page":"2741","article-title":"Guidelines for the Management of Atopic Dermatitis 2024","volume":"134","author":"Japanese Dermatological Association","year":"2024","journal-title":"Japanese Journal of Dermatology"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint American Academy of Dermatology\u2010National Psoriasis Foundation Guidelines of Care for the Management of Psoriasis With Topical Therapy and Alternative Medicine Modalities","volume":"84","author":"Menter A.","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The Eczema Area and Severity Index (EASI): Assessment of Reliability in Atopic Dermatitis","volume":"10","author":"Hanifin J. M.","year":"2001","journal-title":"Experimental Dermatology"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","article-title":"Evaluating Psoriasis With Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment","volume":"51","author":"Langley R. G.","year":"2004","journal-title":"Journal of the American Academy of Dermatology"},{"key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two\u2010Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods","volume":"17","author":"Newcombe R. G.","year":"1998","journal-title":"Statistics in Medicine"},{"key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias Reduction of Maximum Likelihood Estimates","volume":"80","author":"Firth D.","year":"1993","journal-title":"Biometrika"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.1047","article-title":"A Solution to the Problem of Separation in Logistic Regression","volume":"21","author":"Heinze G.","year":"2002","journal-title":"Statistics in Medicine"},{"key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving Towards Best Practice When Using Inverse Probability of Treatment Weighting Using the Propensity Score to Estimate Causal Treatment Effects in Observational Studies","volume":"34","author":"Austin P. C.","year":"2015","journal-title":"Statistics in Medicine"},{"key":"e_1_2_10_26_1","volume-title":"Causal Inference: What if","author":"Hernan M. A.","year":"2020"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70448","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.70448","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:19:15Z","timestamp":1786079955000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.70448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":25,"alternative-id":["10.1111\/1346-8138.70448"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.70448","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"2026-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1346-8138.70448"}}